High Growth Tech Stocks In Australia Echo IQ And 2 More To Watch

Simply Wall St.09-01

As the Australian market grapples with inflation concerns mirroring Wall Street's recent performance, the S&P/ASX 200 is expected to open lower despite a positive close last week. In this environment ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2664883108?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-09-01 03:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664883108","market":"sg","top_or_hot":-1,"title":"High Growth Tech Stocks In Australia Echo IQ And 2 More To Watch","media":"Simply Wall St.","content":"<div>\n<p>As the Australian market grapples with inflation concerns mirroring Wall Street's recent performance, the S&P/ASX 200 is expected to open lower despite a positive close last week. In this environment ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/high-growth-tech-stocks-in-australia-echo-iq-and-2-more-to-w\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>High Growth Tech Stocks In Australia Echo IQ And 2 More To Watch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHigh Growth Tech Stocks In Australia Echo IQ And 2 More To Watch\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-09-01 03:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/high-growth-tech-stocks-in-australia-echo-iq-and-2-more-to-w><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As the Australian market grapples with inflation concerns mirroring Wall Street's recent performance, the S&P/ASX 200 is expected to open lower despite a positive close last week. In this environment ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/high-growth-tech-stocks-in-australia-echo-iq-and-2-more-to-w\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EIQ.AU","symbol_name":"ECHOIQ LTD","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/high-growth-tech-stocks-in-australia-echo-iq-and-2-more-to-w","article_id":"2664883108","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/high-growth-tech-stocks-in-australia-echo-iq-and-2-more-to-w","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2664883108","pubTimestamp":1788203178,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"As the Australian market grapples with inflation concerns mirroring Wall Street's recent performance, the S&P/ASX 200 is expected to open lower despite a positive close last week. In this environment of economic uncertainty and fluctuating indices, high-growth tech stocks like Echo IQ are gaining attention for their potential to thrive through innovation and adaptability, making them compelling options for investors seeking growth opportunities in a volatile market landscape.","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"EIQ.AU":"ECHOIQ LTD","BK7016":"应用软件","ELS.AU":"ELSIGHT LTD","BK4108":"电影和娱乐","VAS.AU":"VANGUARD AUST SHARES IDX ETF","OZF.AU":"SPDR S&P/ASX 200 FINANCIALS","EUFX":"ProShares Short Euro ETF","EIGA.AU":"EINVEST INCOME GENERATOR FD","XAO.AU":"标普/澳交所 普通股指数","BK4552":"Archegos爆仓风波概念","IMLC.AU":"INV MUTUAL CONC AUS SHAR ETF","BK7067":"生物科技","OZR.AU":"SPDR S&P/ASX 200 RESOURCES F","IIGF.AU":"Intelligent Investor Australian Equity Growth Fund (Managed Fund)","XJO.AU":"标普/澳交所 200指数","BK7501":"新冠治疗股","E200.AU":"SPDR S&P/ASX 200 ESG FUND","GEAR.AU":"BETASHARES GEARED AUS EQTY F","GIVE.AU":"PERPETUAL ESG AU SHR EQMF","XKO.AU":"标普/澳交所 300指数","IISV.AU":"INTELL INV SELVAL SHR FD MF","BBOZ.AU":"BETASHARES AUSTRALIAN STRONG BEAR (HEDGE FUND)","BK7084":"电子设备和仪器","BK4531":"中概回港概念","BK4526":"热门中概股","USD":"ProShares Ultra Semiconductors","IQ":"爱奇艺","STW.AU":"SPDR® S&P/ASX 200 ETF","QFN.AU":"BetaShares Australian Fincls Sect ETF","IOZ.AU":"iShares Core S&P/ASX 200","BK7508":"医药生物股","BEAR.AU":"BETASHARES AUS EQ BEAR HF","MSB.AU":"MESOBLAST LTD","CROC":"ProShares UltraShort Australian Dollar ETF","DACE.AU":"DIMENSIONAL AUST CORE EQ","QRE.AU":"BetaShares Australian Res Sect ETF","BK4505":"高瓴资本持仓","SLF.AU":"SPDR S&P/ASX 200 LISTED PROP","VAP.AU":"VANGUARD AU PROP SEC IDX ETF","ZYAU.AU":"Etfs S&p/asx 300 High Yield Plus Etf"},"translate_title":"澳大利亚高增长科技股 Echo IQ 和另外 2 只值得关注","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLF.AU":0.6,"EIQ.AU":1,"XJO.AU":1.5,"STW.AU":0.6,"CROC":0.9,"IIGF.AU":0.6,"E200.AU":0.6,"BEAR.AU":0.6,"ZYAU.AU":0.6,"GIVE.AU":0.6,"MSB.AU":1,"IISV.AU":0.6,"OZF.AU":0.6,"VAS.AU":0.6,"XKO.AU":1.5,"VAP.AU":0.6,"BBOZ.AU":0.6,"QFN.AU":0.6,"IQ":0.77,"EIGA.AU":0.6,"QRE.AU":0.6,"OZR.AU":0.6,"EUFX":0.77,"GEAR.AU":0.6,"XAO.AU":1.5,"DACE.AU":0.6,"USD":0.77,"IOZ.AU":0.6,"ELS.AU":1,"IMLC.AU":0.6},"content_text":"As the Australian market grapples with inflation concerns mirroring Wall Street's recent performance, the S&P/ASX 200 is expected to open lower despite a positive close last week. In this environment of economic uncertainty and fluctuating indices, high-growth tech stocks like Echo IQ are gaining attention for their potential to thrive through innovation and adaptability, making them compelling options for investors seeking growth opportunities in a volatile market landscape.AdvertisementTop 3 High Growth Tech Companies In AustraliaNameRevenue GrowthEarnings GrowthGrowth RatingElsight45.55%58.55%★★★★★★Ion Video136.03%138.78%★★★★★★Echo IQ73.93%69.11%★★★★★★Mesoblast36.71%51.29%★★★★★★Click here to see the full list of 4 stocks from our ASX High Growth Tech and AI Stocks screener.We'll examine a selection from our screener results.Echo IQ (ASX:EIQ)Simply Wall St Growth Rating: ★★★★★★Overview: Echo IQ Limited provides artificial intelligence diagnostics tools to enhance the diagnosis of structural heart disease in Australia, with a market cap of A$1.05 billion.Operations: The company focuses on developing AI software to improve structural heart disease diagnosis, generating revenue of A$0.09 million from this segment.Echo IQ, amid a challenging financial landscape with a net loss widening to AUD 18.57 million from AUD 13.26 million year-over-year, continues to invest in innovation and growth opportunities. The company's recent follow-on equity offering raised AUD 110 million, underscoring investor confidence and bolstering its capital for further development of its AI-driven EchoSolv platform. This strategic move is complemented by a significant partnership with Mayo Clinic to enhance cardiac risk stratification using Echo IQ’s AI technology in oncology patients, highlighting its commitment to expanding the application of its solutions in critical healthcare areas. With projected revenue growth at an impressive annual rate of 73.9% and earnings expected to surge by 69.1% annually, Echo IQ is positioning itself as a key player in leveraging artificial intelligence for substantial advancements in medical technology despite current profitability challenges.Navigate through the intricacies of Echo IQ with our comprehensive health report here.Gain insights into Echo IQ's historical performance by reviewing our past performance report.ASX:EIQ Revenue and Expenses Breakdown as at Aug 2026Elsight (ASX:ELS)Simply Wall St Growth Rating: ★★★★★★Overview: Elsight Limited develops and commercializes connectivity solutions across Europe, Israel, the United States, and internationally with a market cap of A$1.15 billion.Operations: Elsight Limited focuses on electronic security devices, generating revenue of $41.37 million from this segment.Elsight, transitioning from a loss to profitability this year, showcases robust financial health with a notable surge in sales from USD 4.85 million to USD 23.42 million and a swing to net income of USD 1.19 million. This growth trajectory is underpinned by strategic expansions in the U.S. and Germany, enhancing its manufacturing capabilities to meet increasing demand from defense sectors globally. The company's forward-looking approach also includes exploring acquisitions to bolster its technological edge and market presence, reflecting an aggressive growth strategy with projected annual revenue and earnings increases of 45.6% and 58.5%, respectively.Click here to discover the nuances of Elsight with our detailed analytical health report.Assess Elsight's past performance with our detailed historical performance reports.ASX:ELS Revenue and Expenses Breakdown as at Aug 2026Mesoblast (ASX:MSB)Simply Wall St Growth Rating: ★★★★★★Overview: Mesoblast Limited, along with its subsidiaries, focuses on developing regenerative medicine products in Australia and has a market capitalization of A$3.06 billion.Operations: The company generates revenue primarily through the development and commercialization of its allogeneic cellular medicines platform, amounting to $120.25 million.Mesoblast Limited, amid a challenging landscape for unprofitable biotech firms, has demonstrated a promising growth trajectory with its revenue soaring to USD 120.25 million from USD 17.2 million in just one year, marking an annual increase of 36.7%. This surge is underpinned by significant advancements in its clinical trials, notably the MSB-DR004 Phase 3 trial for chronic low back pain treatment which could potentially tap into a market exceeding USD 10 billion. Despite current unprofitability and a net loss reduction to USD 57.5 million from USD 102.14 million, Mesoblast's strategic focus on regenerative medicine and high forecasted return on equity of 22.1% positions it uniquely within the high-stakes biotech sector, anticipating profitability within three years bolstered by innovative therapies and strong regulatory engagements.Unlock comprehensive insights into our analysis of Mesoblast stock in this health report.Evaluate Mesoblast's historical performance by accessing our past performance report.ASX:MSB Revenue and Expenses Breakdown as at Aug 2026Key TakeawaysGet an in-depth perspective on all 4 ASX High Growth Tech and AI Stocks by using our screener here.Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.Want To Explore Some Alternatives?Explore high-performing small cap companies that haven't yet garnered significant analyst attention.Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.Find companies with promising cash flow potential yet trading below their fair value.  This article by Simply Wall St is general in nature. We provide commentary based on historical data \n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your \n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data. \n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. \n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Elsight might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2664883108","isCrawlerRequest":true}